WHO stops HCQ and combination of HIV drug trials

Geneva [Switzerland], Saturday: The World Health Organisation has halted its trials of the malaria drug hydroxychloroquine and combination of HIV drug lopinavir/ritonavir for the treatment of hospitalised COVID-19 patients after they failed to reduce the death rate, Al Jazeera reported.

The WHO was quoted as saying in a statement, “These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalised COVID-19 patients when compared to the standard of care. Solidarity trial investigators will interrupt the trials with immediate effect,”.

It has been further added by the WHO that this decision will now also affect the other studies where the drugs are being used for non-hospitalised or as prophylaxis.The WHO has reported a total of 212,326 new cases of coronavirus globally in 24 hours.

  • Related Posts

    ‘Import of Refurbished Medical Devices’ Lobby has reared its Ugly Head

    Domestic Medical Device Leaders cry foul against move to do away with Policy Restrictions New Delhi:  The union government mandarins seem to be at it again, diametrically opposed to Prime…

    Indigenous Robotic Surgery is Mantra for Accessible Cancer Care in India

    Best in Class ‘Made in India’ Surgical Robot is proving Best Bet New Delhi: ‘Made in India’ best in class surgical robot SSiMantra is proving godsend for cancer patients in…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise